The Sequel Of Advanced Maternal Age On Regulation Of Anti- Mullerian Hormone, Quality Of Oocytes, Embryo Competency And Pregnancy Outcomes In Intracytoplasmic Sperm Injection Cycles
DOI:
https://doi.org/10.52783/jns.v14.3904Keywords:
Advanced maternal age, assisted reproductive technology, anti-Müllerian hormone, embryo quality, oocytes, pregnancyAbstract
Advanced maternal age (AMA), defined as 35 years or older, significantly affects fertility due to diminished ovarian reserve (DOR), reduced oocyte quality, and decreased embryo competency. With a growing trend of delayed childbearing, AMA has become a key factor in the increasing demand for assisted reproductive technology (ART). This study aims to assess the impact of AMA on anti-Mullerian hormone (AMH) levels, oocyte quality, embryo competence, and pregnancy outcomes in intracytoplasmic sperm injection (ICSI) cycles. This retrospective study involved 240 women undergoing ICSI cycles at the Bliss Fertility Centre in Kottayam, Kerala, between January 2022 and August 2024. Participants were categorized into five age groups, and data were collected on AMH levels, oocyte quality, embryo grade, and pregnancy outcomes. AMH levels were measured using chemiluminescence immune assays, and oocyte morphology was assessed microscopically. Statistical analyses included logistic regression and chi-square tests. The mean AMH level across the cohort was 2.83 2.05 ng/mL, with significantly lower levels observed in women aged 37 years. Good-quality oocytes were retrieved in 88.4% of women aged 25–31, but only 43.2% of those aged 37 ( 0.05). Embryo competency, measured by the percentage of good-quality embryos, was not significantly different across age groups ( 0.808). Pregnancy outcomes declined with increasing age; women aged 25–31 had a 68.4% positive outcome rate, compared to 27% in women aged 37 ( ). Logistic regression highlighted that younger maternal age significantly increased the odds of achieving positive outcomes (OR: 5.85; 95% CI: 2.51–13.61). This study highlights the urgent need for early fertility interventions and ART strategies for AMA patients to optimize reproductive outcomes
Downloads
Metrics
References
García, D., Vassena, R., Prat, A., & Vernaeve, V. (2017). Poor knowledge of age-related fertility decline and assisted reproduction among healthcare professionals. Reproductive Biomedicine Online, 34(1), 32-37.
Damario, M. A., Davis, O. K., & Rosenwaks, Z. (1999). The role of maternal age in the assisted reproductive technologies. Reproductive Medicine Review, 7(1), 41-60.
Pal, L., & Santoro, N. (2003). Age-related decline in fertility. Endocrinology and Metabolism Clinics, 32(3), 669-688.
Cimadomo, D., Fabozzi, G., Vaiarelli, A., Ubaldi, N., Ubaldi, F. M., & Rienzi, L. (2018). Impact of maternal age on oocyte and embryo competence. Frontiers in endocrinology, 9, 327.
Di Clemente, N., Racine, C., Pierre, A., & Taieb, J. (2021). Anti-Müllerian hormone in female reproduction. Endocrine reviews, 42(6), 753-782.
Dolleman, M., Verschuren, W. M. M., Eijkemans, M. J. C., Dollé, M. E. T., Jansen, E. H. J. M., Broekmans, F. J. M., & Van der Schouw, Y. T. (2013). Reproductive and lifestyle determinants of anti-Müllerian hormone in a large population-based study. The Journal of Clinical Endocrinology & Metabolism, 98(5), 2106-2115.
Fragouli, E., Alfarawati, S., Spath, K., & Wells, D. (2014). Morphological and cytogenetic assessment of cleavage and blastocyst stage embryos. Molecular human reproduction, 20(2), 117-126.
Fragouli, E., Alfarawati, S., Spath, K., & Wells, D. (2014). Morphological and cytogenetic assessment of cleavage and blastocyst stage embryos. Molecular human reproduction, 20(2), 117-126.
Cimadomo, D., Fabozzi, G., Vaiarelli, A., Ubaldi, N., Ubaldi, F. M., & Rienzi, L. (2018). Impact of maternal age on oocyte and embryo competence. Frontiers in endocrinology, 9, 327.
Mani, S., Ghosh, J., Coutifaris, C., Sapienza, C., & Mainigi, M. (2020). Epigenetic changes and assisted reproductive technologies. Epigenetics, 15(1-2), 12-25.
Nelissen, E. C., Dumoulin, J. C., Busato, F., Ponger, L., Eijssen, L. M., Evers, J. L., ... & van Montfoort, A. P. (2014). Altered gene expression in human placentas after IVF/ICSI. Human Reproduction, 29(12), 2821-2831.
Lean, S. C., Derricott, H., Jones, R. L., & Heazell, A. E. (2017). Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis. PloS one, 12(10), e0186287.
Vaillant, I., & Paszkowski, J. (2007). Role of histone and DNA methylation in gene regulation. Current opinion in plant biology, 10(5), 528-533.
Brugo-Olmedo, S., Chillik, C., & Kopelman, S. (2001). Definition and causes of infertility. Reproductive biomedicine online, 2(1), 173-185.
Aghajani, S., Salehzadeh, A., Ghasemiyan, F., Mehrafza, M., & Hosseini, A. (2021). The impact of maternal age on chromosomal aneuploidy, blastocyst quality, and pregnancy outcomes during intracytoplasmic sperm injection cycles. Journal of Advanced Biomedical Sciences, 11(4), 4107-4117.
Wang, X., Tian, P. Z., Zhao, Y. J., Lu, J., Dong, C. Y., & Zhang, C. L. (2024). The association between female age and pregnancy outcomes in patients receiving first elective single embryo transfer cycle: a retrospective cohort study. Scientific Reports, 14(1), 19216.
Gunasheela, D., Murali, R., Appaneravanda, L. C., Gerstl, B., Kumar, A., Sengeetha, N., ... & Chandrikadevi, P. M. (2021). Age-specific distribution of serum anti-mullerian hormone and antral follicle count in Indian infertile women. Journal of Human Reproductive Sciences, 14(4), 372-379.
Zhao, D., Fan, J., Wang, P., Jiang, X., Yao, J., & Li, X. (2021). Age-specific definition of low anti-Mullerian hormone and associated pregnancy outcome in women undergoing IVF treatment. BMC Pregnancy and Childbirth, 21, 1-10.
Havrljenko, J., Kopitovic, V., Pjevic, A. T., Milatovic, S., Pavlica, T., Andric, N., & Pogrmic-Majkic, K. (2023). The Prediction of IVF Outcomes with Autologous Oocytes and the Optimal MII Oocyte/Embryo Number for Live Birth at Advanced Maternal Age. Medicina, 59(10), 1799.
Fancsovits, P., Lehner, A., Kaszas, Z., Nemes, A., Dudas, B., Murber, A., ... & Urbancsek, J. (2023). Intracytoplasmic sperm injection does not improve the outcome of IVF treatments in patients with advanced maternal age or low oocyte number: a randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction, 52(8), 102625.
Lebovitz, O., Michaeli, M., Aslih, N., Poltov, D., Estrada, D., Atzmon, Y., & Shalom-Paz, E. (2021). Embryonic development in relation to maternal age and conception probability. Reproductive Sciences, 28, 2292-2300.
Liu, L., Lu, Y., Zhang, P., Sun, Y., Ma, C., & Li, Y. (2020). The risk of advanced maternal age: causes and overview. Journal of Gynecological Research and Obstetrics, 6(1), 019-023.
Glick, I., Kadish, E., & Rottenstreich, M. (2021). Management of pregnancy in women of advanced maternal age: improving outcomes for mother and baby. International journal of women's health, 751-759.
Kortekaas, J. C., Kazemier, B. M., Keulen, J. K., Bruinsma, A., Mol, B. W., Vandenbussche, F., ... & De Miranda, E. (2020). Risk of adverse pregnancy outcomes of late‐and postterm pregnancies in advanced maternal age: A national cohort study. Acta obstetricia et gynecologica Scandinavica, 99(8), 1022-1030.
Meczekalski, B., Czyzyk, A., Kunicki, M., Podfigurna-Stopa, A., Plociennik, L., Jakiel, G., ... & Lukaszuk, K. (2016). Fertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessment. Journal of endocrinological investigation, 39, 1259-1265.
Cedars, M. I. (2022). Evaluation of female fertility—AMH and ovarian reserve testing. The Journal of Clinical Endocrinology & Metabolism, 107(6), 1510-1519.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
